Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported data demonstrating that its first-in-class KRASG12D(ON) inhibitors induced tumor regressions in a preclinical model of human pancreatic cancer carrying an oncogenic KRASG12D mutation.
This first public disclosure of results showing anti-tumor activity for potent inhibitors of the notorious KRASG12D(ON) cancer protein was made by Steve Kelsey, M.D., president of research and development, in a presentation entitled “Approaches to Inhibiting RAS Driven Tumors Beyond KRASG12C” at the 2nd Annual RAS-Targeted Drug Development Conference. Read more . . .